FDA Signals Flexibility as Lexeo’s Gene Therapy for Rare Disease Advances Toward Faster Approval
Lexeo Therapeutics announced a significant regulatory development this week: the U.S. Food and Drug Administration (FDA) is open to a faster approval pathway for the company’s promising gene therapy, LX2006,…